Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

NZ sharemarket dips as F&P Healthcare, Infratil shares fall
Markets Market Close

NZ sharemarket dips as F&P Healthcare, Infratil shares fall

The country’s biggest company fell in value on Wednesday, driving the NZX down.

Tom Raynel 23 Jul 2025
SkyCity swipes right on regulators, but maybe left on revenue
Markets

SkyCity swipes right on regulators, but maybe left on revenue

Mandatory carded play is now in place across all of SkyCity’s NZ properties.

Dileepa Fonseka 23 Jul 2025
Trade buyers likely to scoop Fletcher’s construction division
Markets

Trade buyers likely to scoop Fletcher’s construction division

Buyer interest is expected from Australia and further afield.

NZ market falls on weak export data, S&P/NZX 50 down 0.99%
Markets Market Close

NZ market falls on weak export data, S&P/NZX 50 down 0.99%

New Zealand shares end weaker despite renewed corporate activity.

Jamie Gray 22 Jul 2025